Intravenous Infusion of Zidovudine (AZT) in Children with HIV Infection

Harold W. Lischner; Stephen A. Raphael; David P. Schor; Margaret C. Fisher; Adamadia Deforest; James J. Riviello; Leroy R. Sharer; Leon G. Epstein; Philip A. Pizzo; Pim Brouwers; David G. Poplack; Frank Balis; Howard Moss

doi:10.1056/NEJM198903233201212

Intravenous Infusion of Zidovudine (AZT) in Children with HIV Infection

Harold W. Lischner, Stephen A. Raphael, David P. Schor, Margaret C. Fisher, Adamadia Deforest, James J. Riviello, Leroy R. Sharer, Leon G. Epstein, Philip A. Pizzo, Pim Brouwers, David G. Poplack, Frank Balis, Howard Moss

New Jersey Medical School (NJMS), Pathology

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

To the Editor: Preliminary reports suggest that zidovudine (AZT) has a positive risk-to-benefit ratio in some children with human immunodeficiency virus (HIV) infection. We believe, however, that Pizzo et al. (Oct. 6 issue)¹ did not provide data to justify their conclusion to that effect. Information is lacking regarding (1) the extent to which entry into the study resulted in changes in the home environment or care, nutritional or other therapy, supportive services to the child and family, or educational opportunities; (2) probable differences in the timing and settings (e.g., in relation to stressful associations) of the initial as compared with…

Original language	English (US)
Pages (from-to)	805-806
Number of pages	2
Journal	New England Journal of Medicine
Volume	320
Issue number	12
DOIs	https://doi.org/10.1056/NEJM198903233201212
State	Published - Mar 23 1989

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.1056/NEJM198903233201212

Cite this

@article{41b8cfc9f9214efe8d99b28b277fdf00,

title = "Intravenous Infusion of Zidovudine (AZT) in Children with HIV Infection",

abstract = "To the Editor: Preliminary reports suggest that zidovudine (AZT) has a positive risk-to-benefit ratio in some children with human immunodeficiency virus (HIV) infection. We believe, however, that Pizzo et al. (Oct. 6 issue)1 did not provide data to justify their conclusion to that effect. Information is lacking regarding (1) the extent to which entry into the study resulted in changes in the home environment or care, nutritional or other therapy, supportive services to the child and family, or educational opportunities; (2) probable differences in the timing and settings (e.g., in relation to stressful associations) of the initial as compared with…",

author = "Lischner, {Harold W.} and Raphael, {Stephen A.} and Schor, {David P.} and Fisher, {Margaret C.} and Adamadia Deforest and Riviello, {James J.} and Sharer, {Leroy R.} and Epstein, {Leon G.} and Pizzo, {Philip A.} and Pim Brouwers and Poplack, {David G.} and Frank Balis and Howard Moss",

year = "1989",

month = mar,

day = "23",

doi = "10.1056/NEJM198903233201212",

language = "English (US)",

volume = "320",

pages = "805--806",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "12",

}

TY - JOUR

T1 - Intravenous Infusion of Zidovudine (AZT) in Children with HIV Infection

AU - Lischner, Harold W.

AU - Raphael, Stephen A.

AU - Schor, David P.

AU - Fisher, Margaret C.

AU - Deforest, Adamadia

AU - Riviello, James J.

AU - Sharer, Leroy R.

AU - Epstein, Leon G.

AU - Pizzo, Philip A.

AU - Brouwers, Pim

AU - Poplack, David G.

AU - Balis, Frank

AU - Moss, Howard

PY - 1989/3/23

Y1 - 1989/3/23

N2 - To the Editor: Preliminary reports suggest that zidovudine (AZT) has a positive risk-to-benefit ratio in some children with human immunodeficiency virus (HIV) infection. We believe, however, that Pizzo et al. (Oct. 6 issue)1 did not provide data to justify their conclusion to that effect. Information is lacking regarding (1) the extent to which entry into the study resulted in changes in the home environment or care, nutritional or other therapy, supportive services to the child and family, or educational opportunities; (2) probable differences in the timing and settings (e.g., in relation to stressful associations) of the initial as compared with…

AB - To the Editor: Preliminary reports suggest that zidovudine (AZT) has a positive risk-to-benefit ratio in some children with human immunodeficiency virus (HIV) infection. We believe, however, that Pizzo et al. (Oct. 6 issue)1 did not provide data to justify their conclusion to that effect. Information is lacking regarding (1) the extent to which entry into the study resulted in changes in the home environment or care, nutritional or other therapy, supportive services to the child and family, or educational opportunities; (2) probable differences in the timing and settings (e.g., in relation to stressful associations) of the initial as compared with…

UR - http://www.scopus.com/inward/record.url?scp=0024547810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024547810&partnerID=8YFLogxK

U2 - 10.1056/NEJM198903233201212

DO - 10.1056/NEJM198903233201212

M3 - Letter

C2 - 2633749

AN - SCOPUS:0024547810

SN - 0028-4793

VL - 320

SP - 805

EP - 806

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 12

ER -

Intravenous Infusion of Zidovudine (AZT) in Children with HIV Infection

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this